Insurance remains one of the hardest walls between cannabis and the patients who need it. Despite expanding medical programs, most plans still refuse to cover cannabis products, leaving patients to pay out of pocket and pushing many toward the illicit market. For...
Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocybin and MDMA across pain, treatment-resistant depression, PTSD, and neurological conditions. Yet the field still...
Compliance never sleeps in cannabis, and packaging and labeling sit at the center of it. Cultivators, processors, retailers, and distributors all carry the same weight: rules that shift by state, child-resistant requirements, warning statements, THC limits, and...
Banking access remains one of the cannabis industry’s hardest constraints, and it shapes nearly all growth decisions operators make. Despite years of legislative momentum, most cannabis businesses still run cash-heavy operations, struggle to secure traditional...
Interstate commerce is no longer a distant possibility. As a post-rescheduling framework takes shape, the operators who prepare now will own the first-mover advantage when state borders open to legal trade. This session gives cannabis leaders an understanding of...
